A phenylbutazone dose-finding study in rheumatoid arthritis
| Autor: | P. D. Fowler, W. W. Downie, Howard A. Bird, Verna Wright, J. R. Lowe, P A Leatham |
|---|---|
| Rok vydání: | 1983 |
| Předmět: |
Adult
Male Arthritis Oxyphenbutazone Pharmacology Arthritis Rheumatoid Phenylbutazone medicine Humans Pharmacology (medical) Aged Dose-Response Relationship Drug business.industry Half-life General Medicine Plasma levels Middle Aged medicine.disease Phenylbutazone Dose Dose–response relationship Rheumatoid arthritis Female business Half-Life medicine.drug |
| Zdroj: | European Journal of Clinical Pharmacology. 24:773-776 |
| ISSN: | 1432-1041 0031-6970 |
| DOI: | 10.1007/bf00607086 |
| Popis: | Different doses of phenylbutazone have been compared in a double blind study on 32 patients with rheumatoid arthritis in order to determine the minimum effective dose. Of 8 different dose levels studied (90 mg, 150 mg, 180 mg, 240 mg, 270 mg, 300 mg, 360 mg and 450 mg/day) the most efficacious was found to be 300 mg/day. Doses below this did not produce full benefit; no further improvement occurs with higher doses. Although 7/32 patients developed adverse reactions there was no relationship between these and the plasma levels of either phenylbutazone or oxyphenbutazone. An attempt was made to distinguish 'responders' from 'non-responders'. We found no relationship between response and plasma levels of phenylbutazone or oxyphenbutazone. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink